TNFSF10 and cancer: Clinical trials for TRAIL-based cancer therapies usingeither recombinant forms of the human TRAIL extracellular domain (dulanermin) oragonistic antibodies specifically targeting DR4 (mapatumumab) or DR5 (e.g.conatumumab) also revealed the safety and tolerability of these therapeutics.However, clinical trials of TRAIL-based therapies have failed to producesignificant therapeutic responses in patients [38, 40, 41].